vents and performance to differ materially from those referred to
in such statements. Accordingly, the company claims the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release is
as of the date of the release and Transgenomic does not undertake any duty
to update this information, including any forward-looking statements,
unless required by law.
Transgenomic, Inc.
Summary Financial Results
Unaudited Condensed Consolidated Statements of Operations
(dollars in thousands except per share data)
Three Months Six Months
Ended Ended
June 30 June 30
2007 2006 2007 2006
NET SALES $6,272 $6,189 $11,494 $12,686
COST OF GOODS SOLD 2,859 3,140 5,373 6,654
Gross profit 3,413 3,049 6,121 6,032
OPERATING EXPENSES:
Selling, general and
administrative 3,067 2,820 6,047 5,529
Research and development 492 531 1,550 1,135
Restructuring costs 624 -- 624 --
4,183 3,351 8,221 6,664
LOSS FROM OPERATIONS (770) (302) (2,100) (632)
OTHER INCOME (EXPENSE):
Interest income, net of
interest expense 79 44 141 88
Other, net -- -- 4 --
Gain on sale of i
'/>"/>
SOURCE Transgenomic, Inc.
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
TomoTherapy reports 86% revenue jump, $131M net loss in Q12.
Sonic Foundry reports GAAP loss as Q2 revenues rise3.
Fiserv reports $113.5 million in Q1 profit4.
Third Wave reports net loss of $18.9M for 20065.
Musicnotes reports 45 percent growth in 20066.
Sonic Foundry reports net loss, higher revenue7.
Sonic Foundry reports first cash-positive quarter8.
Merge Healthcare reports $10.8M net loss in Q39.
Third Wave reports $5.2M third quarter loss10.
Merge Healthcare appoints new CEO, reports $215 million Q2 loss11.
Merge files financial reports by market opening